Summary
Sparfloxacin is a recently developed fluoroquinolone. The drug has shown potent antimicrobial activity against a wide range of Gram-positive and Gram-negative bacteria, glucose nonfermenters, anaerobes, Legionella spp., Mycoplasma spp., Chlamydia spp. and Mycobacterium spp. Methicillin-resistant Staphylococcus aureus is also susceptible to sparfloxacin.
Plasma sparfloxacin concentrations reach a peak (Cmax) of approximately 0.7 mg/L at 3 to 5 hours after a 200mg oral dose. This is followed by a monophasic slow decrease, with an elimination half-life (t½) of 15 to 20 hours. The Cmax and area under the plasma concentration-time curve show dose-related increases. Food intake does not affect the absorption and pharmacokinetics of sparfloxacin.
Sparfloxacin binds weakly to plasma protein (37%), and exhibits excellent tissue distribution and effective penetration into extracellular fluids. Concentrations of the drug in most tissues are similar to, or higher than, concomitant plasma concentrations. Sparfloxacin distributes slightly into cerebrospinal fluid. The drug is metabolised to a glucuronide. The urinary excretion of the unchanged drug accounts for 10 to 14% of the given dose. The ratio of Cmax values after multiple and single oral doses is 1.3 to 1.4, but other pharmacokinetic parameters of sparfloxacin are not influenced by multiple doses.
Even in patients with severe renal failure, no significant prolongation of the half-life is observed after oral administration. Sparfloxacin appears unlikely to affect the pharmacokinetics of theophylline. Antacids containing aluminium hydroxide reduce the oral bioavailability of sparfloxacin by 25 to 35%. Probenecid does not affect sparfloxacin pharmacokinetics. The pharmacokinetic properties of sparfloxacin allow once-daily administration in the treatment of various infections.
Similar content being viewed by others
References
Akiyama H, Torigoe R, Yamada T, Abe Y, Kanamoto A, et al. Sparfloxacin in the field of dermatology. Chemotherapy (Tokyo) 39 (Suppl. 4): 145–148, 1991
Aoki N, Usuda Y, Koda Y, Wakabayashi N, Hayashi S, et al. Clinical pharmacology and efficacy of sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 261–271, 1991
Chang T, Black A, Dunky A, Wolf R, Sedman A, et al. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 21 (Suppl. B): 49–56, 1988
Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, et al. In vitro activity of sparfloxacin (CI-978, AT-4140, and PD-131501): a quinolone with high activity against gram-positive bacteria. Diagnostic Microbiology and Infectious Diseases 14: 403–415, 1991
Cooper MA, Andrews JM, Ashby JP, Mattews RS, Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. Journal of Antimicrobial Chemotherapy 26: 667–676, 1990
Doebbeling BN, Pfaller MA, Bale MJ, Wenzel RP. Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. European Journal of Clinical Microbiology and Infectious Diseases 9: 298–301, 1990
Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrobial Agents and Chemotherapy 30: 440–443, 1986
Giamarellou H, Voutsinas D, Xirouchaki E. Comparative in vitro activity of sparfloxacin (AT4140, RP-64206, SPFX) against 275 multiresistant clinical isolates. Journal of Chemotherapy 4: 12–15, 1992
Goto H, Goto M, Oka S, Urayama K, Kimura S, et al. Evaluation of antibacterial activity of sparfloxacin using in vitro pharmacokinetic system. Chemotherapy (Tokyo) 39 (Suppl. 4): 54–58, 1991a
Goto S, Miyazaki S, Tsuji A, Kaneko Y. In vitro and in vivo antibacterial activities of a new quinolone, sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 13–29, 1991b
Gouhara Y, Oowaki T, Shimizu Y. Fundamental and clinical studies on sparfloxacin (SPFX). Chemotherapy (Tokyo) 39 (Suppl. 4): 497–503, 1991
Hara J, Ozawa T, Araki K, Mitsuda H. Sparfloxacin in anterior eye infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 697–700, 1991
Harada Y, Hirakawa K, Tagashira N, Suzuki M, Kawamura S, et al. Clinical studies of sparfloxacin against suppurative otitis media. Chemotherapy (Tokyo) 39 (Suppl. 4): 670–680, 1991
Imagawa Y, Saito M, Matsubara Y, Tomizawa I, Takizawa Y, et al. Clinical study of sparfloxacin on infectious enteritis. Chemotherapy (Tokyo) 39 (Suppl. 4): 454–465, 1991
Ito K, Mikamo H, Tamaya T, Yamada Y, Hayashi M, et al. Sparfloxacin in the obstetrical and gynecological field. Chemotherapy (Tokyo) 39 (Suppl. 4): 719–725, 1991
Kaji M, Saito A, Shimada J, Ohmori M, Shiba K, et al. Clinical studies on NY-198. Chemotherapy (Tokyo) 36 (Suppl. 2): 513–526, 1988
Kato M, Kuze F. In vitro activities of a new quinolone derivative, sparfloxacin, against Mycobacterium tuberculosis, Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium fortuitum. Chemotherapy (Tokyo) 39 (Suppl. 4): 101–106, 1991
Kawada Y, Kumamoto Y, Aso Y, Oshi M, Machida T, et al. Comparative study of sparfloxacin and enoxacin in complicated urinary tract infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 571–588, 1991
Kawahara K, Kawahara M, Goto T, Ohi Y. Penetration of sparfloxacin into the human spinal fluid: a comparative study with 5 other fluoroquinolones. Chemotherapy (Tokyo) 39 (Suppl. 4): 149–157, 1991
Kawai S, Yada K, Hida T, Fujiwara T. Basic and clinical studies of sparfloxacin in the field of ophthalmology. Rinsho Ganka 45: 1891–1894, 1991
Kojima T, Inoue M, Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 33: 1980–1988, 1989
Kurobe N, Ohue T, Yamaguchi T, Nakamura S. Bioassay method for sparfloxacin in body fluids. Chemotherapy (Tokyo) 39 (Suppl. 4): 116–122, 1991
Lode H, Hoeffken G, Olschewski P, Sievers B, Kirch A, et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrobial Agents and Chemotherapy 31: 1338–1342, 1987
Mahr G, Seelmann R, Gottschalk B, Stephan U, Sorgel F. No effect of sparfloxacin on the metabolism of theophylline in man. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 296, Atlanta, October 21–24, 1990
Matsunaga Y, Miyazaki H, Oh-e Y, Nambu K, Furukawa H, et al. Disposition and metabolism of [14C]sparfloxacin in the rat. Arzneimittel-Forschung 41 (2): 747–759, 1991
Matsushima T, Kawanishi M, Kimura M, Tomizawa S, Kobashi Y, et al. Clinical study of sparfloxacin in respiratory infections and its concentration in pleural fluid. Chemotherapy (Tokyo) 39 (Suppl. 4): 798–803, 1991
Matsuura T, Adachi S, Suzuki K, Yamamoto T. Basic and clinical studies on sparfloxacin in elderly subjects. Chemotherapy (Tokyo) 39 (Suppl. 4): 286–291, 1991
Mignot A, Douin MJ, Millerioux L, Chassard D, Thebault JJ, et al. Effect of aluminum hydroxide antacid on the pharmacokinetics of the new quinolone sparfloxacin. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, Abstract no. 1250, p. 294, 1990
Miki F, Ikuno Y, Murata A, Tanizawa S, Sakamoto K, et al. Basic and clinical studies of sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 292–305, 1991
Miyamoto T, Matsumoto J, Chiba K, Egawa H, Shibamori K, et al. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. Journal of Medicinal Chemistry 33: 1645–1656, 1990
Mizuki Y, Kamaura M, Yamaguchi Y, Sekine Y, Hashimoto M. Interaction of enoxacin with theophylline in rats. Arzneimittel-Forschung 39: 593–597, 1989
Mizuki Y, Yamaguchi T, Sekine Y, Hashimoto M. Effect of sparfloxacin on theophylline pharmacokinetics in rats. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, Abstract no. 1252, p. 295, 1990
Montay G, Bruno R, Thebault JJ, Vergniol JC, Chassard D, et al. Dose-dependent pharmacokinetic study of sparfloxacin (SPFX) in healthy young volunteers. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, Abstract no. 1248, p. 294, 1990
Morimoto K, Kinoshita H, Nakatani S, Lee K, Sakai K, et al. Sparfloxacin in the treatment of patients with surgical infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 601–619, 1991
Murakami T, Nakahara K, Matsuo M, Masaoka T, Fujiwara A. Sparfloxacin in obstetrics and gynecology. Chemotherapy (Tokyo) 39 (Suppl. 4): 734–740, 1991
Naitoh H, Tomita F. Serum levels and saliva concentration of sparfloxacin (SPFX). Shiyaku Ryouhou 10: 85–90, 1991
Nakamura S, Kurobe N, Ohue T, Hashimoto M, Shimizu M. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrobial Agents and Chemotherapy 34: 89–93, 1990
Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, at al. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrobial Agents and Chemotherapy 33: 1167–1173, 1989
Nakamura S, Nakata K, Kashimoto S, Kajikawa F, Okazaki Y, et al. Antichlamydial activity of sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 93–100, 1991
Nakashima M, Kanamaru M, Uematsu T, Takiguchi Y. Phase I study of pyridone carboxylic acid antibacterial agent, sparfloxacin. Rinshou Iyaku 7: 1639–1684, 1991
Nakashima M, Uematsu T, Kanamaru M, Naganuma H. Clinical pharmacology of antimicrobial pyridonecarboxylic acids (I): comparative study on pharmacokinetics in healthy humans and antimicrobial activity. Chemotherapy (Tokyo) 38: 533–539, 1990
Nakatani T, Tsuboi E, Narui K, Chonabayashi N, Nakamori Y, et al. Clinical efficacy of sparfloxacin in the respiratory tract infections and its pharmacokinetics in sputum. Chemotherapy (Tokyo) 39 (Suppl. 4): 245–249, 1991
Niki T, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone anti-bacterial agents and serum concentration of theophylline. Chest 92: 663–669, 1987
Nishino T, Nakamura M, Wano T, Otsuki M. In vitro and in vivo antibacterial activities of sparfloxacin, a new quinolone. Chemotherapy (Tokyo) 39 (Suppl. 4): 59–77, 1991
Nogita T, Ishibashi Y. The penetration of sparfloxacin into human plasma and skin tissue. Journal of Antimicrobial Chemotherapy 28: 313–314, 1991
Oguri T, Hayashi Y. In vitro activity of sparfloxacin against clinical isolates. Chemotherapy (Tokyo) 39 (Suppl. 4): 37–46, 1991
Oishi K, Matsumoto K, Watanabe K, Takasugi M, Utsunomiya Y, et al. In vitro activity, pharmacokinetics and therapeutic efficacy of sparfloxacin, a new quinolone: usefulness in lower respiratory infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 366–377, 1991
Okimoto N, Niki Y, Sumi M, Nakagawa Y, Soejima R. Effect of sparfloxacin on plasma concentration of theophylline. Chemotherapy (Tokyo) 39 (Suppl. 4): 158–160, 1991
Onodera S, Kiyota H, Goto H, Kawahara M, Igarashi H, et al. Clinical efficacy of sparfloxacin in genitourinary tract infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 481–488, 1991
Qadri SM, Ueno Y, Burns JJ, Alomodovar E, Rabea N. In vitro activity of sparfloxacin (CI978), a new broad-spectrum fluoroquinolone. Chemotherapy (Switzerland) 38: 99–106, 1992
Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. American Journal of Medicine 82 (Suppl. 4A): 115–118, 1987
Saito A, Tomizawa M, Nakayama I, Sato K. Basic and clinical studies on sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 203–212, 1991
Sakashita S, Yokogawa M, Yamaguchi T, Sekine Y. Pharmacokinetics of sparfloxacin in man. Xenobiotic Metabolism and Disposition 6: 43–51, 1991
Sato A, Okano A, Chida K, Iwata M, Okano H, et al. Basic and clinical studies on sparfloxacin in respiratory tract infection. Chemotherapy (Tokyo) 39 (Suppl. 4): 272–279, 1991
Shimada J, Saito A, Shiba K, Hojo T, Kaji M, et al. Pharmacokinetics and clinical studies of sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 234–244, 1991
Shimada J, Yamaji T, Ueda Y, Uchida H, Kasajima H, et al. Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrobial Agents and Chemotherapy 23: 1–7, 1983
Soejima R, Kawame H, Okimoto N, Sumi M, Saito A, et al. Comparative study of sparfloxacin and ofloxacin in bacterial pneumonia by the double blind method. Chemotherapy (Tokyo) 39 (Suppl. 4): 428–453, 1991b
Soejima R, Kawane H, Okimoto N, Tatara O, Takebe K, et al. Comparative study of sparfloxacin and ofloxacin in chronic respiratory tract infections by the double blind method. Chemotherapy (Tokyo) 39 (Suppl. 4): 405–428, 1991a
Stuck AE, Frey FJ, Heizmann P, Brandt R, Weidekmann E. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 33: 373–381, 1989
Suzuki K, Horiba M, Naide Y, Shinoda M, Hibi H. Clinical and bacteriological study of sparfloxacin on bacterial prostatitis. Hinyokika Kiyou 38: 121–128, 1992
Takagi K, Yamaki K, Nadai M, Kuzuya T, Hasegawa T. Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. Antimicrobial Agents and Chemotherapy 35: 1137–1141, 1991
Takahashi H, Mochizuki A, Takahashi N, Nishikawa T, Amano Y, et al. A multicenter double blind comparative study of sparfloxacin and enoxacin in the treatment of skin and soft tissue infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 648–669, 1991
Takamoto M, Kitahara Y, Ishibashi T, Shinoda A. Clinical trial experience with sparfloxacin against respiratory infections and pharmacokinetic analysis. Chemotherapy (Tokyo) 39 (Suppl. 4): 337–341, 1991
Takeuchi T, Yamamoto N, Takahashi Y, Shinoda I, Ito Y, et al. Pharmacokinetic analysis on penetration of sparfloxacin into prostatic tissue. Chemotherapy (Tokyo) 39 (Suppl. 4): 138–144, 1991
Tanimura H, Ishimoto K, Yukawa H, Sakamoto Y, Ohnishi H, et al. Excretion into bile and gallbladder tissue level of a new quinolone, sparfloxacin, and its clinical efficacy on surgical infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 620–632, 1991a
Tanimura M, Kataoka S, Fujita Y. Basic and clinical studies of sparfloxacin in urinary tract infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 523–530, 1991b
Thebault JJ, Montay G, Ebmeier M, Douin MJ, Millerioux L, et al. Effect of food on the bioavailability of the new quinolone sparfloxacin. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, Abstract no. 1249, p. 294, 1990
Toyoura T, Morishima T. Blood levels of exodontia wound after oral administration of sparfloxacin (AT-4140). Shiyaku Ryouhou 10: 91–96, 1991
Uchizono A, Shima T, Ohyama M, Fukami K, Miyazaki Y, et al. Penetration of sparfloxacin into tissues and secretions in bacterial infections in otolaryngological field. Jibi to Rinsho 37: 941–948, 1991
Ueda S, Eto K. Fundamental and clinical studies on sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 538–544, 1991
Watanabe K, Kato N, Muto Y, Bando K, Tanaka Y, et al. In vitro activities of a new quinolone, sparfloxacin, against anaerobic bacteria. Chemotherapy (Tokyo) 39 (Suppl. 4): 107–115, 1991
Weidekamm E, Portmann R, Partos C, Dell D, Lucker PW. Single and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrobial Agents and Chemotherapy 31: 1909–1914, 1987
Wijnands WJA, Vree TB, Baars AM, van Herwaarden CLA. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. Journal of Antimicrobial Chemotherapy 21 (Suppl. B): 67–77, 1988
Wijnands WJA, Vree TB, van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. British Journal of Clinical Pharmacology 22: 677–683, 1986
Wingender W, Beermann D, Foster D. Mechanism of renal excretion of ciprofloxacin (Bay 9867), a new quinolone carboxylic derivative, in humans. Chemotherapy 4 (Suppl. 2): 403–404, 1985
Yamada H, Katoh O, Hiura K, Aoki Y, Kuroki S, et al. Clinical effects of sparfloxacin on respiratory tract infections and penetration of this agent into sputum. Chemotherapy (Tokyo) 39 (Suppl. 4): 350–356, 1991
Yamaguchi T, Yokogawa M, Hashizume T, Baba M, Higuchi Y, et al. Pharmacokinetics of sparfloxacin in rats, dogs and monkeys. Xenobiotic Metabolism and Disposition 6: 33–41, 1991a
Yamaguchi T, Yokogawa M, Sakashita M, Itokawa A, Kurono M, et al. Metabolism of sparfloxacin in rats, dogs, monkeys and man. Xenobiotic Metabolism and Disposition 6: 2132, 1991c
Yamaguchi T, Yokogawa M, Sekine Y. Renal excretion mechanism of sparfloxacin. Xenobiotic Metabolism and Disposition 6: 61–65, 1991d
Yamaguchi T, Yokogawa M, Sekine Y, Hashimoto M. Intestinal absorption characteristics of sparfloxacin. Xenobiotic Metabolism and Disposition 6: 53–59, 1991b
Yamamoto Y, Matsumoto S, Ikeda M, Kodama H. Penetration of sparfloxacin into the skin. Chemotherapy (Tokyo) 39 (Suppl. 4): 741–742, 1991
Yokota T, Kanda K, Arai K. In vitro antibacterial activity of sparfloxacin, its synergy with the complement of mouse cultured macrophages in the bactericidal effect, and cytotoxicity to mammalian cells. Chemotherapy (Tokyo) 39 (Suppl. 4): 30–36, 1991
Yoshitomi Y, Mitsutake K, Higashiyama Y, Matsuda H, Miyazaki Y, et al. Laboratory and clinical studies on sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 357–365, 1991
Yura J, Shinagawa N, Ishikawa S, Mashita K, Suzui K, et al. Basic and clinical studies on sparfloxacin in the field of surgery. Chemotherapy (Tokyo) 39 (Suppl. 4): 594–600, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shimada, J., Nogita, T. & Ishibashi, Y. Clinical Pharmacokinetics of Sparfloxacin. Clin. Pharmacokinet. 25, 358–369 (1993). https://doi.org/10.2165/00003088-199325050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199325050-00002